Endo Withdraws Opana Painkiller From Market at FDA’s Request Post author:Sam Post published:July 6, 2017 Post category:Drug Industry Daily Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily You Might Also Like U.S. Has Spare Capacity for Generic Drug Production, Survey Finds October 4, 2022 FDA Changes Approach to Homeopathic Products, Sharpless Says October 24, 2019 Maryland Considers Laws Requiring Drugmakers to Justify Price Increases and Publish Cost Data February 23, 2017
Maryland Considers Laws Requiring Drugmakers to Justify Price Increases and Publish Cost Data February 23, 2017